Literature DB >> 26380653

Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Hisashi Nakayama1, Tadatoshi Takayama1.   

Abstract

The global distribution of hepatocellular carcinoma (HCC) varies markedly among regions, and patients in East Asia and Central Africa account for about 80% of all cases. The risk factors are hepatitis B, hepatitis C, alcohol, and etc. The risk of carcinogenesis further increases with progression to hepatic cirrhosis in all liver disorders. Radical treatment of HCC by liver resection without causing liver failure has been established as a safe approach through selection of an appropriate range of resection of the damaged liver. This background indicates that both evaluation of hepatic functional reserve and measures against concomitant diseases such as thrombocytopenia accompanying portal hypertension, prevention of rupture of esophageal varices, reliable control of ascites, and improvement of hypoalbuminemia are important issues in liver resection in patients with hepatic cirrhosis. We review the latest information on perioperative management of liver resection in HCC patients with hepatic cirrhosis.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver cirrhosis; Liver resection; Portal hypertension

Year:  2015        PMID: 26380653      PMCID: PMC4568489          DOI: 10.4254/wjh.v7.i20.2292

Source DB:  PubMed          Journal:  World J Hepatol


  99 in total

Review 1.  Hepatitis B virus infection.

Authors:  Christian Trépo; Henry L Y Chan; Anna Lok
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

2.  Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.

Authors:  Jianhua Yin; Nan Li; Yifang Han; Jie Xue; Yang Deng; Jie Shi; Weixing Guo; Hongwei Zhang; Hongyang Wang; Shuqun Cheng; Guangwen Cao
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

3.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

4.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 5.  Overwhelming post splenectomy infection syndrome - review study.

Authors:  Prabhu Dayal Sinwar
Journal:  Int J Surg       Date:  2014-11-07       Impact factor: 6.071

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Damien Lucidarme; Juliette Foucher; Brigitte Le Bail; Julien Vergniol; Laurent Castera; Clotilde Duburque; Gérard Forzy; Bernard Filoche; Patrice Couzigou; Victor de Lédinghen
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

8.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

9.  The role of splenectomy in patients with hepatocellular carcinoma and secondary hypersplenism.

Authors:  Jae Won Oh; Soo Min Ahn; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Byung Ro Kim
Journal:  Yonsei Med J       Date:  2003-12-30       Impact factor: 2.759

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  4 in total

1.  miRNA-346 promotes proliferation, migration and invasion in liver cancer.

Authors:  Qiang Yu; Xia Yang; Weidong Duan; Chonghui Li; Ying Luo; Shichun Lu
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

2.  Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis.

Authors:  Ying Ding; Shengxiang Rao; Li Yang; Caizhong Chen; Mengsu Zeng
Journal:  Radiol Med       Date:  2016-07-23       Impact factor: 3.469

Review 3.  Recent Advances of Microbiome-Associated Metabolomics Profiling in Liver Disease: Principles, Mechanisms, and Applications.

Authors:  Ganesan Raja; Haripriya Gupta; Yoseph Asmelash Gebru; Gi Soo Youn; Ye Rin Choi; Hyeong Seop Kim; Sang Jun Yoon; Dong Joon Kim; Tae-Jin Kim; Ki Tae Suk
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

4.  Notoamide-type alkaloid induced apoptosis and autophagy via a P38/JNK signaling pathway in hepatocellular carcinoma cells.

Authors:  Likun Hu; Ting Zhang; Dong Liu; Guiwen Guan; Jian Huang; Peter Proksch; Xiangmei Chen; Wenhan Lin
Journal:  RSC Adv       Date:  2019-06-25       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.